Spinal Cord Injury Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of SCI, historical and forecasted epidemiology, as well as the SCI market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Spinal Cord Injury Market with DelveInsight's In-Depth Report @ Spinal Cord Injury Market Size- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Spinal Cord Injury Market Report
In June 2025, NervGen Pharma announced a study of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments. To evaluate safety and tolerability of NVG-291 in a SCI population, as measured by clinical assessments (Physical Examination, Vital Signs, ECG, etc.) as well as clinical laboratory measures.
In June 2025, Ashibio Inc. conducted a study of andecaliximab in participants at risk of developing bone where bone should not be, such as in muscle, tendons, and other soft tissues following traumatic spinal cord injury. The goal of this study is to assess the safety of andecaliximab, how much drug is in the body over time (pharmacokinetics/PK), and how it affects the body (pharmacodynamics/PD) in participants who have had a recent traumatic spinal cord injury.
In 2023, there were an estimated 959 thousand total diagnosed prevalent cases of SCI across the 7MM, with the number expected to rise by 2034.
According to DelveInsight's estimates, there were approximately 19 thousand acute (incidence) cases of SCI across the US in 2023, with the number expected to rise by 2034.
According to DelveInsight's estimates, there were approximately 308 thousand diagnosed prevalent cases of SCI across the US in 2023, with the number expected to rise by 2034.
In 2023, the US reported approximately 247 thousand male and 62 thousand female cases of SCI, with these numbers expected to increase by 2034.
According to DelveInsight's estimates, there were approximately 537 thousand diagnosed prevalent cases of SCI across EU4 and the UK in 2023, with the number expected to rise by 2034.
In 2023, in the UK, there were approximately 92 thousand diagnosed prevalent cases of traumatic SCI and 14 thousand cases of non-traumatic SCI. These numbers are expected to rise to 99 thousand and 15 thousand cases, respectively, by 2034.
In 2023, Japan recorded approximately 20% of traumatic SCI cases due to vehicular accidents, 55% due to falls, 5% each due to violence, sports-related injuries, and medical/surgical causes, and 10% due to other factors.
The leading Spinal Cord Injury Companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others.
Promising Spinal Cord Injury Pipeline Therapies such as NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others.

Discover which therapies are expected to grab the major spinal cord injury market share @ Spinal Cord Injury Market Report- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Spinal Cord Injury Epidemiology Segmentation in the 7MM
Total Spinal Cord Injury Cases
Spinal Cord Injury Diagnosed Cases
Spinal Cord Injury Gender-specific Cases
Spinal Cord Injury Cause-specific Cases
Total cases of SCI at Neurological Level

Download the report to understand which factors are driving Spinal Cord Injury epidemiology trends @ Spinal Cord Injury Prevalence- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Spinal Cord Injury Treatment Market
In the initial care of a patient with a spinal cord injury, the foremost priority is to establish and secure the airway, ensure proper breathing, and maintain circulation. This is followed by the crucial step of immobilizing the spine in the field to prevent any further harm to the vulnerable spinal cord during transportation. It is of paramount importance to recognize and triage SCI patients appropriately in the early stages to guarantee the prompt delivery of specialized treatments at dedicated centers.

Spinal Cord Injury Marketed Drugs
STEMIRAC: Nipro Corporation
STEMIRAC, developed by Nipro Corporation, is an autologous mesenchymal stem cell (MSC) therapy designed to treat traumatic SCI. It involves isolating MSCs from the patient's bone marrow, culturing them in vitro, and cryopreserving them for future use. Administered via intravenous infusion, these MSCs home to the site of injury, where they exert therapeutic effects through immunomodulation, anti-inflammatory actions, and secretion of trophic factors, promoting tissue repair and functional recovery.

Spinal Cord Injury Emerging Drugs
KP-100IT: Kringle Pharma
KP-100IT, developed by Kringle Pharma, is being investigated for the treatment of acute SCI. The drug aims to support nerve cell protection and enhance axonal extension, potentially aiding in motor function recovery after SCI. Positive Phase I/II results demonstrated a promising safety and efficacy profile in patients with severe acute cervical SCI. The completed Phase III study, which began in July 2020, evaluated KP-100IT's efficacy in improving recovery outcomes, with the primary endpoint focused on achieving at least a two-grade improvement in the American Spinal Injury Association (ASIA) score within six months.

Neuro-Cells: Neuroplast
Neuro-Cells, developed by Neuroplast, is an innovative stem cell therapy designed for treating TSCI, to reduce inflammation and promote nerve regeneration within the central nervous system. By aiming to preserve and restore function, mobility, and independence, Neuro-Cells represents a significant advancement in TSCI treatment.

MT-3921: Mitsubishi Tanabe Pharma Corporation
MT-3921, developed by Mitsubishi Tanabe Pharma Corporation (MTPC) in collaboration with Osaka University, aimed at treating SCI. By targeting repulsive guidance molecule A (RGMa), which inhibits neuronal survival and regeneration, MT-3921 seeks to promote neuroregeneration and improve motor function in SCI patients. The US FDA granted Fast Track Designation (FTD) in July 2021.

To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Spinal Cord Injury Therapies and Companies
NVG-291: NervGen Pharma
Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation
Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
MT-3921: Mitsubishi Tanabe Pharma America Inc.
Elezanumab: AbbVie

Learn more about the FDA-approved drugs for spinal cord injury @ Drugs for Spinal Cord Injury Treatment- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Spinal Cord Injury Market Dynamics
The dynamics of the spinal cord injury market are expected to change in the coming years. Both academic institutions and industries are actively pursuing advanced approaches to the development of innovative therapies. Recent advancements in comprehending the pathophysiology of spinal cord injuries have triggered a notable increase in clinical trials. Continuous dedication to basic and clinical research is forging a new path toward regenerative medicine in SCI. Nevertheless, the lack of an efficient therapy to target SCI-related symptoms and complications remains a pressing issue.

Get In-Depth Knowledge on Spinal Cord Injury Market Trends and Forecasts with DelveInsight @ Spinal Cord Injury Treatment Market- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Spinal Cord Injury Market Report
Study Period: 2020-2034
Coverage: 7MM
Spinal Cord Injury Companies: NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others
Spinal Cord Injury Therapies: NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others
Therapeutic Assessment: Spinal Cord Injury, current marketed and emerging therapies
Spinal Cord InjuryMarket Dynamics: Conjoint Analysis of Emerging Spinal Cord Injury Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Spinal Cord Injury Market Access and Reimbursement

Discover more about spinal cord injury drugs in development @ Spinal Cord Injury Clinical Trials- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Spinal Cord Injury Market Key Insights
2. Spinal Cord Injury Market Report Introduction
3. Spinal Cord Injury Market Overview at a Glance
4. Spinal Cord Injury Market Executive Summary
5. Disease Background and Overview
6. Spinal Cord Injury Treatment and Management
7. Spinal Cord Injury Epidemiology and Patient Population
8. Patient Journey
9. Spinal Cord Injury Marketed Drugs
10. Spinal Cord Injury Emerging Drugs
11. Seven Major Spinal Cord Injury Market Analysis
12. Spinal Cord Injury Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

radial artery compression device market- https://www.delveinsight.com/report-store/transradial-access-products-market
vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
cone rod dystrophy market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
opioid-related disorders market- https://www.delveinsight.com/report-store/opioid-related-disorders-market
adeno associated viruses aav gene therapy market- https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight
cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
methicillin-resistant staphylococcus aureus infection market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
atopic dermatitis market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
cardiogenic shock market- https://www.delveinsight.com/report-store/early-cardiogenic-shock-cs-market
chemotherapy induced neutropenia market- https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
CXCR inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
friedreich's ataxia market- https://www.delveinsight.com/report-store/friedreichs-ataxia-market
herpes labialis market- https://www.delveinsight.com/report-store/herpes-labialis-market
herpes zoster market- https://www.delveinsight.com/report-store/herpes-zoster-market
somatotropin deficiency market- https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market
spinal trauma devices market- https://www.delveinsight.com/report-store/trauma-devices-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
atherosclerosis market- https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
chronic heart failure market- https://www.delveinsight.com/report-store/heart-failure-market
chronic venous ulceration market- https://www.delveinsight.com/report-store/chronic-venous-ulceration-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
hypertrophic cardiomyopathy market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
langerhans cell histiocytosis market- https://www.delveinsight.com/report-store/langerhans-cell-histiocytosis-market
liver fibrosis market- https://www.delveinsight.com/report-store/liver-fibrosis-market
membranous nephropathy market- https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
plaque modification devices market- https://www.delveinsight.com/report-store/plaque-modification-devices-market
primary ciliary dyskinesia market- https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market
psoriasis vulgaris market- https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
radiodermatitis market- https://www.delveinsight.com/report-store/radiation-dermatitis-market
ranibizumab biosimilars market- https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
seasonal allergic rhinitis market- https://www.delveinsight.com/report-store/allergic-rhinitis-market
sly syndrome market- https://www.delveinsight.com/report-store/sly-syndrome-market
social anxiety disorder market- https://www.delveinsight.com/report-store/social-anxiety-disorder-market
soft tissue sarcoma with lung metastasis market- https://www.delveinsight.com/report-store/soft-tissue-sarcoma-with-lung-metastases-market
surgical bleeding market- https://www.delveinsight.com/report-store/surgical-bleeding-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.